30 Nov -0001
Rockville, Md. The global peptide based cancer therapeutics market is set to surpass US$ 11.1 Bn by 2022 on above-average growth, according to Fact.MR, as rising cancer incidence meets steady progress in drug modification, stability, delivery and preclinical development. A pipeline of new peptides with encouraging early results is moving through clinical trials, and the shortcomings of conventional therapies are steering physicians toward peptide-based options.
North America is the most attractive region, bortezomib leads by drug, and hospital pharmacies carry most sales. Asia Pacific excluding Japan is the fastest-growing region.
Bortezomib is the leading drug at about 40% of revenue, with more than US$ 4.7 Bn expected to sell by 2022. On distribution, hospital pharmacies dominate at close to 50% of revenue, followed by retail pharmacies, a pattern set to hold through the forecast period.
North America stays the most attractive region on the strength of established peptide drug makers and advanced healthcare infrastructure, while Asia Pacific excluding Japan posts the fastest CAGR.
The market runs on clinical need. With cancer among the leading causes of death worldwide, the World Health Organization recorded over 8 million cancer deaths in 2015, demand for more effective, better-tolerated therapies keeps rising, and peptide-based drugs are drawing interest as an alternative to lower-potency conventional treatments with harsher side effects.
The field brings together large pharmaceutical companies.
For drug makers, growth favours continued product development and R&D investment. Investors get a market with a firm clinical tailwind and above-average growth. Procurement and hospital teams can plan around bortezomib carrying volume, hospital pharmacies leading distribution, and North America offering the largest opportunity through 2022.
Fact.MR's study covers the global peptide based cancer therapeutics market for the 2017 to 2022 forecast period, with segmentation by drug, distribution channel and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the peptide based cancer therapeutics market report.
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.
Peptide-based Cancer Therapeutics Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.